Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.
Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.
CiteAb’s founder Dr Andrew Chalmers said that data highlighting the number of academic research papers using antibodies produced by each country “clearly shows that China is the big winner at the moment. The United States has been the most productive nation in bioscience research for a long time, but has seen a gradual decrease in output since 2010.”
He added: “Conversely, China’s output has been growing enormously since around 2009 and if current trends continue we expect to see China overtake the USA by as soon as 2020. To counter this, the USA will need to increase investment in bioscience research.”
Data published by the company also suggests that Japan’s share of the world’s bioscience output has gradually fallen since 2009. Germany and Britain appear to remain stable, said Chalmers, “so they are likely to become the third and fourth most active bioscience research nations as Japan drops down.”
Bioscience research funding increased in China by 33 per cent a year between 2007 and 2012, whereas the U.S. has seen a decrease of 2 per cent a year. Chalmers added: “We know that China’s most recent five year plan makes research in this sector a priority for the country… The quality is also there - we can see that an increasing number of papers from Chinese researchers are being published by top journals.”
CiteAb, an antibody search engine listing over 1.8million antibodies and ranking them by over 300,000 academic citations, spun out from the University of Bath, UK, earlier this year.
The company’s first market report is available here: http://blog.citeab.com/first-citeab-market-report-puts-spotlight-on-chinese-bioscience-growth
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.